PET radiopharmaceuticals: What's new, what's reimbursed, and what's next?

Abstract

The field of molecular imaging is undergoing a period of expansion. The number of radiopharmaceutical ligands, therapeutic isotope combinations, and targets continues to grow, with several new PET agents being approved over the last few years for diseases such as neuroendocrine tumor and prostate cancer. We will need to work together as a community to effectively use and advance these promising agents.